How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

248 results for

Interstitial Brachytherapy for Prostate Cancer

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Interstitial low-dose-rate brachytherapy for localized prostate cancer - rapid report

Interstitial low-dose-rate brachytherapy for localized prostate cancer - rapid report 1 Translation of the key statement of the rapid report N17-04 Interstitielle Low-Dose-Rate-Brachytherapie beim lokal begrenzten Prostatakarzinom (Version 1.0; Status: 19 October 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding (...) . Extract IQWiG Reports – Commission No. N17-04 Interstitial low-dose-rate brachytherapy for localized prostate cancer 1 Extract of rapid report N17-04 Version 1.0 Brachytherapy for prostate cancer 19 October 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Interstitial low-dose-rate brachytherapy for localized prostate cancer Commissioning agency: Federal Joint Committee Commission awarded

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

2. Padeliporfin (Tookad) - prostate cancer / Prostatic Neoplasms

the Committee, issued a positive opinion for granting a marketing authorisation to Tookad on 14 September 2017. 2. Scientific discussion 2.1. Problem statement 2.1.1. Disease or condition Tookad is indicated as monotherapy for adult patients with previously untreated, unilateral, low-risk, adenocarcinoma of the prostate with a life expectancy = 10 years and: - Clinical stage T1c or T2a, - Gleason Score = 6, based on high-resolution biopsy strategies, - PSA = 10 ng/mL, - 3 positive cancer cores (...) Padeliporfin (Tookad) - prostate cancer / Prostatic Neoplasms 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 14 September 2017 EMA/644309/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report TOOKAD International non-proprietary name: padeliporfin Procedure No. EMEA/H/C/004182/0000 Note Assessment report

2017 European Medicines Agency - EPARs

3. Low dose rate (LDR) brachytherapy for intermediate and high-risk prostate cancer

in the type of additional radiation delivered as a ‘boost’. Subsequent ‘boost’ may be delivered as additional doses of the same procedure (DE-EBRT), through permanent implantation of LDR-BT seeds, or through temporary HDR-BT (Duchesne 2011). The comparators are currently funded by the MBS, and match those in the ratified PICO. In Australia, the CA stated that the most commonly used treatment modalities for localised prostate cancer include surgery, radiotherapy (external beam or interstitial brachytherapy (...) Low dose rate (LDR) brachytherapy for intermediate and high-risk prostate cancer 1 Public Summary Document Application No. 1525 - Low dose-rate (LDR) brachytherapy for intermediate and high-risk prostate cancer Applicant: BXTAccelyon Australia Pty Ltd Date of MSAC consideration: MSAC 76 th Meeting, 1-2 August 2019 Context for decision: MSAC makes its advice in accordance with its Terms of Reference, visit the MSAC website 1. Purpose of application An application requesting Medicare Benefits

2020 Medical Services Advisory Committee

4. Brachytherapy for Patients With Prostate Cancer Full Text available with Trip Pro

to this disease. Additional information is available at and . INTRODUCTION Section: The goal of this update is to provide oncologists, other health care practitioners, patients, and caregivers with recommendations regarding the use of brachytherapy for patients with prostate cancer that includes the most recent evidence. Prostate cancer is the most commonly diagnosed cancer in men. In 2016, it is estimated that there will be 180,890 new cases, along with an estimated 26,120 deaths. For this reason (...) , there is great interest in finding optimum treatment strategies to reduce the burden of disease in this patient population. The Cancer Care Ontario systematic review and clinical practice guideline on low–dose rate (LDR) brachytherapy for patients with low- or intermediate-risk prostate cancer were both published in 2013, and since then randomized evidence has been made available that might alter the original recommendations. The goal of this joint update is to consider this new evidence and determine

2017 American Society of Clinical Oncology Guidelines

5. Interstitial brachytherapy in localized prostate cancer - Update

Interstitial brachytherapy in localized prostate cancer - Update Executive Summary IQWiG Reports – Commission No. N10-01 Interstitial brachytherapy in localized prostate cancer – Update 1 1 Translation of the executive summary of the rapid report “Interstitielle Brachytherapie beim lokal begrenzten Prostatakarzinom – Update” (Version 1.0; Status: 13.12.2010). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text (...) is absolutely authoritative and legally binding. Executive summary of rapid report N10-01 Version 1.0 Brachytherapy in prostate cancer 13.12.2010 Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Interstitial brachytherapy in localized prostate cancer – Update Contracting agency: Federal Joint Committee Commission awarded on: 27.04.2010 Internal Commission No.: N10-01 Address of publisher: Institute for Quality and Efficiency in Health Care Dillenburger Str. 27 51105

2011 Institute for Quality and Efficiency in Healthcare (IQWiG)

6. Comparison of prostate contours between conventional stepping transverse imaging and Twister-based sagittal imaging in permanent interstitial prostate brachytherapy Full Text available with Trip Pro

Comparison of prostate contours between conventional stepping transverse imaging and Twister-based sagittal imaging in permanent interstitial prostate brachytherapy To compare prostate contours on conventional stepping transverse image acquisitions with those on twister-based sagittal image acquisitions.Twenty prostate cancer patients who were planned to have permanent interstitial prostate brachytherapy were prospectively accrued. A transrectal ultrasonography probe was inserted (...) , with the patient in lithotomy position. Transverse images were obtained with stepping movement of the transverse transducer. In the same patient, sagittal images were also obtained through rotation of the sagittal transducer using the "Twister" mode. The differences of prostate size among the two types of image acquisitions were compared. The relationships among the difference of the two types of image acquisitions, dose-volume histogram (DVH) parameters on the post-implant computed tomography (CT) analysis

2017 Journal of contemporary brachytherapy

7. Interstitial Brachytherapy for Prostate Cancer

Interstitial Brachytherapy for Prostate Cancer Interstitial Brachytherapy for Prostate Cancer Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer (...) Administration 4 Interstitial Brachytherapy for Prostate Cancer Interstitial Brachytherapy for Prostate Cancer Aka: Interstitial Brachytherapy for Prostate Cancer , Prostate Seed Implant Radiotherapy II. Indications Localized (Stages A to C) III. Technique Permanent radioactive seed implants into 125 Palladium 103 Seeds precisely geometric arranged by computer IV. Efficacy Appears effective as conventional V. Advantages over External Beam Prostate Radiotherapy Higher radiation dose with less adverse effects

2018 FP Notebook

8. Permanent Source Brachytherapy for Prostate Cancer

the Cesium Advisory Group. Brachytherapy. 2008;7(4):290-296. 55. Cohen GN, Amols HI, Zelefsky MJ, Zaider M. The Anderson nomograms for permanent interstitial prostate implants: a briefing for practitioners. Int J Radiat Oncol Biol Phys. 2002;53(2):504-511. 56. Davis BJ, Pisansky TM, Wilson TM, et al. The radial distance of extraprostatic extension of prostate carcinoma: implications for prostate brachytherapy. Cancer. 1999;85(12):2630-2637. 57. Waterman FM, Yue N, Corn BW, Dicker AP. Edema associated (...) Review Introduction/Background Improvements in permanent prostate brachytherapy (PPB) utilizing transrectal ultrasound (TRUS) guidance via a perineal template resulted in this procedure becoming a major treatment option for localized prostate cancer by the mid-1990s [1]. PPB is an outpatient procedure with short treatment time, rapid patient recovery, and demonstrated long-term efficacy. For men with low-risk disease, treatment efficacy is comparable to other primary treatment options [2-5

2016 American College of Radiology

9. Tumour and immune cell dynamics explain the PSA bounce after prostate cancer brachytherapy. Full Text available with Trip Pro

Tumour and immune cell dynamics explain the PSA bounce after prostate cancer brachytherapy. Interstitial brachytherapy for localised prostate cancer may be followed by transient increases in prostate-specific antigen (PSA) that resolve without therapy. Such PSA bounces may be associated with an improved outcome but often cause alarm in the patient and physician, and have defied explanation.We developed a mathematical model to capture the interactions between the tumour, radiation and anti (...) -tumour immune response. The model was fitted to data from a large cohort of patients treated exclusively with interstitial brachytherapy. Immunohistological analysis for T-cell infiltration within the same tumours was also performed.Our minimal model captures well the dynamics of the tumour after therapy, and suggests that a strong anti-tumour immune response coupled with the therapeutic effect of radiation on the tumour is responsible for the PSA bounce. Patients who experience a PSA bounce had

2016 British Journal of Cancer

10. Salvage Brachytherapy and Interstitial Hyperthermia for Locally Recurrent Prostate Carcinoma Following Radiation Therapy

external beam radiation therapy. Condition or disease Intervention/treatment Phase Prostate Cancer Radiation: Brachytherapy Other: Hyperthermia Not Applicable Detailed Description: Salvage brachytherapy in combination with interstitial hyperthermia for locally recurrent prostate carcinoma following external beam radiation therapy: Salvage brachytherapy: HDRBT: 3 x 10 Gy specified on prostate capsule/tumor margin (d1, 22, 43) or PDRBT: 2 x 30 Gy specified on prostate capsule/tumor margin (d1-3, 29-31 (...) Salvage Brachytherapy and Interstitial Hyperthermia for Locally Recurrent Prostate Carcinoma Following Radiation Therapy Salvage Brachytherapy and Interstitial Hyperthermia for Locally Recurrent Prostate Carcinoma Following Radiation Therapy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2015 Clinical Trials

11. Dosimetric comparison between treatment plans of patients treated with low-dose-rate vs. high-dose-rate interstitial prostate brachytherapy as monotherapy: Initial findings of a randomized clinical trial. (Abstract)

Dosimetric comparison between treatment plans of patients treated with low-dose-rate vs. high-dose-rate interstitial prostate brachytherapy as monotherapy: Initial findings of a randomized clinical trial. The aim of this study was to compare the dosimetry of intraoperative dose plans of prostate cancer patients treated with low-dose-rate (LDR) and high-dose-rate (HDR) interstitial brachytherapy (BT).A randomized clinical trial was initiated at our institution to compare the results and side (...) effects of LDR and HDR BT as monotherapy in the treatment of early, organ-confined prostate cancer patients. Eighty-seven patients were randomly assigned to receive HDR afterloading BT with one fraction of 19 Gy or permanent LDR 125I seed BT with 145 Gy. Inverse optimization algorithms were used for planning. Stranded seeds were implanted using live ultrasound imaging after preimplant treatment planning. Final dosimetry of HDR treatments was based on updated needle and contour positions. Statistical

2017 Brachytherapy Controlled trial quality: uncertain

12. 5-Year Outcomes of a Single Institution Prospective Trial of 19 Gy Single-Fraction HDR Brachytherapy for Low- and Intermediate-Risk Prostate Cancer. (Abstract)

volumes >50 cm3, taking alpha-blockers for urinary symptoms, or with baseline American Urologic Association symptom scores >12 were ineligible. Patients underwent transrectal ultrasound-guided interstitial implant of the prostate followed by single-fraction HDR brachytherapy to a prescription dose of 19 Gy.Sixty-eight patients were enrolled with a median follow-up of 3.9 years. Median age was 62 years. Median gland volume at the time of treatment was 35 cm3, 92.6% of patients had T1 disease, 63.2% had (...) 5-Year Outcomes of a Single Institution Prospective Trial of 19 Gy Single-Fraction HDR Brachytherapy for Low- and Intermediate-Risk Prostate Cancer. To update outcome and toxicity results of a prospective trial of 19-Gy single-fraction high-dose-rate (HDR) brachytherapy for men with low- and intermediate-risk prostate cancer.Patients were treated on a prospective study of single-fraction HDR brachytherapy. All patients had low- or intermediate-risk prostate cancer. Patients with prostate

2019 Biology and Physics

13. Testosterone Profiles after Brachytherapy for Localized Prostate Cancer. (Abstract)

Testosterone Profiles after Brachytherapy for Localized Prostate Cancer. To evaluate patients' serum total testosterone levels (STLs) after brachytherapy (BT) for prostate cancer.We enrolled 102 men who underwent permanent interstitial BT using I125 without androgen deprivation therapy for localized prostate cancer. Seed BT radiation dose was 145 Gy. Patients were followed for 24-60 months after BT. The primary outcome was STL kinetics after BT. Predictors of testosterone decrease were also (...) period had significantly higher median baseline STLs (median: 5.05 ng/mL) than the group whose STLs decreased by less than 1.00 ng/mL (median: 3.64 ng/mL).Although STL decreased significantly after I125-based BT, STL decline after treatment for localized prostate cancer was not large and recovered over time.Copyright © 2019 Elsevier Inc. All rights reserved.

2019 Urology

14. High-Dose-Rate Brachytherapy Monotherapy versus Image-Guided Intensity-Modulated Radiotherapy with Helical Tomotherapy for Patients with Localized Prostate Cancer Full Text available with Trip Pro

High-Dose-Rate Brachytherapy Monotherapy versus Image-Guided Intensity-Modulated Radiotherapy with Helical Tomotherapy for Patients with Localized Prostate Cancer The aim of this paper is to compare outcomes between high-dose-rate interstitial brachytherapy (HDR-BT) monotherapy and image-guided intensity-modulated radiotherapy (IG-IMRT) for localized prostate cancer. We examined 353 HDR-BT and 270 IG-IMRT patients. To reduce background selection bias, we used the method of inverse probability (...) . For high-risk patients, HDR-BT showed potential to improve prostate-specific antigen (PSA) control rate compared to IG-IMRT.

2018 Cancers

15. HDR Brachytherapy as Monotherapy for Low and Intermediate Risk Prostate Cancer

Information provided by (Responsible Party): Marjory Jolicoeur, CR-CSSS Champlain-Charles-Le Moyne Study Details Study Description Go to Brief Summary: The purpose of this study is to evaluate High-dose rate (HDR) brachytherapy (1 vs 2 fractions on single implant) as monotherapy for the treatment of low risk and intermediate risk prostate cancer Condition or disease Intervention/treatment Phase Prostate Cancer Radiation: HDR brachytherapy as monotherapy Not Applicable Study Design Go to Layout table (...) : No Studies a U.S. FDA-regulated Device Product: No Keywords provided by Marjory Jolicoeur, CR-CSSS Champlain-Charles-Le Moyne: Brachytherapy Monotherapy HDR Brachytherapy Toxicity Quality of Life Progression Free Survival Additional relevant MeSH terms: Layout table for MeSH terms Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site Neoplasms Genital Diseases, Male Prostatic Diseases

2018 Clinical Trials

16. Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer

therapy is an established curative treatment and can be either external-beam radiotherapy or brachytherapy (also called interstitial radiotherapy). Brachytherapy can be given at either low- or high-dose rates. Low-dose-rate brachytherapy may be used alone or in combination with external-beam radiotherapy. 3 3 The procedure The procedure 3.1 Radiotherapy for prostate cancer can cause rectal damage because of the close proximity of the prostate to the rectum. Symptoms include diarrhoea, incontinence (...) Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer Biodegr Biodegradable spacer insertion to reduce rectal adable spacer insertion to reduce rectal to toxicity during r xicity during radiother adiotherap apy for prostate cancer y for prostate cancer Interventional procedures guidance Published: 23 August 2017 nice.org.uk/guidance/ipg590 Y Y our responsibility our responsibility This guidance represents the view of NICE, arrived at after careful

2017 National Institute for Health and Clinical Excellence - Interventional Procedures

17. Seed migration after transperineal interstitial prostate brachytherapy by using loose seeds: Japanese prostate cancer outcome study of permanent iodine-125 seed implantation (J-POPS) multi-institutional cohort study Full Text available with Trip Pro

Seed migration after transperineal interstitial prostate brachytherapy by using loose seeds: Japanese prostate cancer outcome study of permanent iodine-125 seed implantation (J-POPS) multi-institutional cohort study The incidence and associated factors of loose seed migration were investigated in cohort 1 of the Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS).The study subjects were 2160 patients, consisting of 1641 patients who underwent permanent (...)  + EBRT group, respectively. In the PI group, the number of implanted seeds was associated with the seed migration incidence. Neither the PI nor the PI + EBRT group showed any difference in the volume of the prostate receiving 100 % of the prescribed dose (V100 [%]) or the minimal dose received by 90 % of the prostate volume (D90 [Gy]) between the patients with and without seed migration.This prospective cohort study investigating the largest number of past cases showed no difference in D90 (Gy

2015 Radiation oncology (London, England)

18. Prostate Cancer

of malignant tumors. UICC International Union Against Cancer. 8th edn. 2017. 73. Cooperberg, M.R., et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol, 2005. 173: 1938. 74. Epstein, J.I., et al. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol, 2005. 29: 1228 (...) as predictors for prostate cancer. J Clin Oncol, 2009. 27: 398. 133. Stephan, C., et al. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia. Cancer, 1997. 79: 104. 134. Catalona, W.J., et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA, 1998. 279: 1542. 135

2020 European Association of Urology

19. High-Dose-Rate Brachytherapy for Prostate Cancer

. Needle applicator displacement during high-dose-rate interstitial brachytherapy for prostate cancer. Brachytherapy. 2010;9(1):36-41. 19. Yoshioka Y, Konishi K, Sumida I, et al. Monotherapeutic high-dose-rate brachytherapy for prostate cancer: five-year results of an extreme hypofractionation regimen with 54 Gy in nine fractions. Int J Radiat Oncol Biol Phys. 2011;80(2):469-475. 20. Yoshioka Y, Nose T, Yoshida K, et al. High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate (...) . Demanes DJ, Martinez AA, Ghilezan M, et al. High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2011;81(5):1286-1292. 25. Prada PJ, Jimenez I, Gonzalez-Suarez H, Fernandez J, Cuervo-Arango C, Mendez L. High-dose-rate interstitial brachytherapy as monotherapy in one fraction and transperineal hyaluronic acid injection into the perirectal fat for the treatment of favorable stage prostate cancer: treatment description

2013 American College of Radiology

20. After low and high dose-rate interstitial brachytherapy followed by IMRT radiotherapy for intermediate and high risk prostate cancer. Full Text available with Trip Pro

After low and high dose-rate interstitial brachytherapy followed by IMRT radiotherapy for intermediate and high risk prostate cancer. The study aimed to compare urinary symptoms in patients with clinically localized prostate cancer after a combination of either low-dose-rate or high-dose-rate interstitial brachytherapy along with intensity-modulated radiation therapy (LDR-ISBT + IMRT or HDR-ISBT + IMRT).From June 2009 to April 2014, 16 and 22 patients were treated with LDR-ISBT + IMRT and HDR (...) significant association with the IPSS-increment in the irritative urinary symptoms (p = 0.011). Clinical outcomes were comparable between both the groups.Both therapeutic modalities are safe and well suited for patients with clinically localized prostate cancer; however, it took patients longer to recover from LDR-ISBT + IMRT than from HDR-ISBT + IMRT. It is possible that fast dose delivery induced early symptoms and early recovery, while gradual dose delivery induced late symptoms and late recovery

2016 BMC Cancer

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>